Education
About Us
Working with TipRanks
Follow Us
Cidara Therapeutics (CDTX)
NASDAQ:CDTX
CDTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.01 - $28.42
Previous CloseN/A
Volume155.01K
Average Volume (3M)135.51K
Market Cap
$245.25M
Enterprise Value$68.88M
Total Cash (Recent Filing)-$185.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 08, 2025EPS Estimate
-3.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-29.69
Shares Outstanding10,953,490
10 Day Avg. Volume203,807
30 Day Avg. Volume135,513
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)193.04
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.82
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$37.50Price Target Upside67.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyCD388, the lead candidate for preventing influenza, shows significant promise for success due to its novel mechanism, high potency, and positive efficacy in human trials.
Financial StrategyCidara raised $105 million through a private placement to accelerate the start of the Phase 3 trial for CD388.
Market PotentialCidara's novel platform technology has the potential to transform the influenza therapeutic landscape, pointing to a billion-dollar opportunity.
Bears Say
Leadership ChangesA new CFO, Frank Karbe, has assumed the role, potentially bringing fresh leadership to the company's financial strategy.
Market ValuationCidara is considered undervalued, even when only considering the CD388 opportunity in a limited population and geography.
Trial Completion And ResultsThe Ph2b NAVIGATE Flu prevention trial of CD388 completed enrollment, and results are anticipated to be available soon.
---
Ownership Overview
18.54% Insiders
2.08% Mutual Funds
25.96% Other Institutional Investors
51.73% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CDTX FAQ
What was Cidara Therapeutics’s price range in the past 12 months?
Cidara Therapeutics lowest stock price was $10.01 and its highest was $28.42 in the past 12 months.
What is Cidara Therapeutics’s market cap?
Cidara Therapeutics’s market cap is $245.25M.
When is Cidara Therapeutics’s upcoming earnings report date?
Cidara Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 37 days.
How were Cidara Therapeutics’s earnings last quarter?
Cidara Therapeutics released its earnings results on Mar 06, 2025. The company reported -$5.37 earnings per share for the quarter, missing the consensus estimate of -$3.62 by -$1.75.
Is Cidara Therapeutics overvalued?
According to Wall Street analysts Cidara Therapeutics’s price is currently Undervalued.
Does Cidara Therapeutics pay dividends?
Cidara Therapeutics does not currently pay dividends.
What is Cidara Therapeutics’s EPS estimate?
Cidara Therapeutics’s EPS estimate is -3.54.
How many shares outstanding does Cidara Therapeutics have?
Cidara Therapeutics has 10,953,490 shares outstanding.
What happened to Cidara Therapeutics’s price movement after its last earnings report?
Cidara Therapeutics reported an EPS of -$5.37 in its last earnings report, missing expectations of -$3.62. Following the earnings report the stock price went up 0.212%.
Which hedge fund is a major shareholder of Cidara Therapeutics?
Currently, no hedge funds are holding shares in CDTX
---
Cidara Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.50 (67.49% Upside)
$37.50 (67.49% Upside)
Blogger Sentiment
Bullish
CDTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 389.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.68%
12-Months-Change
Fundamentals
Return on Equity
-222.36%
Trailing 12-Months
Asset Growth
214.57%
Trailing 12-Months
Company Description
Cidara Therapeutics
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
---
CDTX Stock 12 Month Forecast
Average Price Target
$37.50
▲(67.49% Upside)
Technical Analysis
Best Analysts Covering CDTX
1 Year
1 Year Success Rate
15/26 ratings generated profit
1 Year Average Return
+25.77%
reiterated a buy rating 22 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 57.69% of your transactions generating a profit, with an average return of +25.77% per trade.
---